Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “First Line Platinum Chemotherapy”

281 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 281 results

Testing effectiveness (Phase 2)Ended earlyNCT06094296
What this trial is testing

BMS-986315 and Nivolumab in Combination With Chemotherapy in Participants With First-line Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)

Who this might be right for
NSCLC
Bristol-Myers Squibb 1
Large-scale testing (Phase 3)Not Yet RecruitingNCT07796100
What this trial is testing

ZL-1310 in Combination With a Checkpoint Inhibitor Versus Standard of Care Platinum Based Chemotherapy With a Checkpoint Inhibitor as First-line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer

Who this might be right for
Extensive-Stage Small Cell Lung Cancer
Zai Lab (Shanghai) Co., Ltd. 530
Large-scale testing (Phase 3)Ended earlyNCT03033511
What this trial is testing

Rovalpituzumab Tesirine as Maintenance Therapy Following First- Line Platinum-Based Chemotherapy in Participants With Extensive Stage Small Cell Lung Cancer (MERU)

Who this might be right for
Small Cell Lung Cancer
AbbVie 748
Large-scale testing (Phase 3)Active Not RecruitingNCT05687266
What this trial is testing

Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations

Who this might be right for
NSCLC
AstraZeneca 1,350
Large-scale testing (Phase 3)Study completedNCT01168973
What this trial is testing

Chemotherapy and Ramucirumab Versus Chemotherapy Alone in Second Line Non-Small Cell Lung Cancer (NSCLC) Participants Who Received Prior First Line Platinum-based Chemotherapy

Who this might be right for
Non-Small Cell Lung Cancer
Eli Lilly and Company 1,253
Testing effectiveness (Phase 2)Looking for participantsNCT04325425
What this trial is testing

Chemotherapy For Metastatic Grade 3 Poorly Differentiated NEuroendocrine Carcinoma Of GastroEnteroPancreatic And Unknown Primary

Who this might be right for
Neuroendocrine Carcinoma
Centre Hospitalier Universitaire Dijon 218
Large-scale testing (Phase 3)Ended earlyNCT06321068
What this trial is testing

BAT1308 in Combination With Platinum-containing Chemotherapy is Used for the First-line Treatment of Advanced or Recurrent dMMR Endometrial Cancer

Who this might be right for
Endometrial Cancer
Bio-Thera Solutions 5
Testing effectiveness (Phase 2)Study completedNCT03980925
What this trial is testing

Platinum-doublet Chemotherapy and Nivolumab for the Treatment of Subjects With Neuroendocrine Neoplasms (NENs) of the Gastroenteropancreatic (GEP) Tract or of Unknown (UK) Origin.

Who this might be right for
Neuroendocrine TumorsNeuroendocrine NeoplasmGastroenteropancreatic Neuroendocrine Tumor
Grupo Espanol de Tumores Neuroendocrinos 37
Testing effectiveness (Phase 2)Looking for participantsNCT06463665
What this trial is testing

Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer

Who this might be right for
Advanced Non-squamous Non-small-cell Lung CancerAdvanced Squamous Non-Small Cell Lung CarcinomaMetastatic Non-squamous Non Small Cell Lung Cancer+5 more
Genelux Corporation 142
Large-scale testing (Phase 3)Looking for participantsNCT07416474
What this trial is testing

RC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC)

Who this might be right for
Non-Small Cell Lung Cancer
RemeGen Co., Ltd. 574
Large-scale testing (Phase 3)Looking for participantsNCT07002346
What this trial is testing

INVIGORATE: A Study of QL1706 and Bevacizumab in Advanced First-Line Ovarian Clear Cell Carcinoma

Who this might be right for
Ovarian Clear Cell Carcinoma
Tongji Hospital 226
Large-scale testing (Phase 3)Active Not RecruitingNCT05668988
What this trial is testing

DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28)

Who this might be right for
Non-small Cell Lung Cancer
Dizal Pharmaceuticals 324
Large-scale testing (Phase 3)UnknownNCT04203485
What this trial is testing

Camrelizumab Combined With Apatinib Mesylate or Camrelizumab Alone for First-line Treatment in Subjects With Programmed Death Ligand 1 (PD-L1) Positive Relapsed or Advanced Non-small Cell Lung Cancer (NSCLC)

Who this might be right for
PD-L1 Positive Non-small Cell Lung Cancer
Jiangsu HengRui Medicine Co., Ltd. 762
Testing effectiveness (Phase 2)UnknownNCT04846452
What this trial is testing

Sintilimab, Anlotinib Hydrochloride and Platinum-Containing Dual-Agent Chemotherapy in NSCLC

Who this might be right for
Metastatic NSCLCRecurrent NSCLCAdvanced Non-Small Cell Squamous Lung Cancer
The First Affiliated Hospital with Nanjing Medical University 40
Testing effectiveness (Phase 2)Study completedNCT01998919
What this trial is testing

Tarceva (Erlotinib) in Combination With Platinum Based Chemotherapy in Patients With Non-Small Cell Lung Cancer.

Who this might be right for
Non-Small Cell Lung Cancer
Hoffmann-La Roche 154
Testing effectiveness (Phase 2)WithdrawnNCT03319316
What this trial is testing

Combination of Durvalumab and Tremelimumab as Maintenance Treatment in Patients With Non Squamous and Squamous (NSCLC)

Who this might be right for
Squamous Non-small Cell Lung CancerNon-Squamous Non-small Cell Lung Cancer
European Organisation for Research and Treatment of Cancer - EORTC
Large-scale testing (Phase 3)Looking for participantsNCT06956001
What this trial is testing

Firmonertinib Versus Platinum Based Chemotherapy as First-line Treatment for NSCLC With EGFR PACC or EGFR l861q Mutation

Who this might be right for
EGFRNSCLC (Advanced Non-small Cell Lung Cancer)
Allist Pharmaceuticals, Inc. 300
Testing effectiveness (Phase 2)Looking for participantsNCT05460000
What this trial is testing

A Phase II Randomized, Open Label Non-inferiority Study of NiraParib Maintenance After 3 vs. 6 Cycles of Platinum-based Chemotherapy in completeLy debUlked Advanced HRDpositive High-grade Ovarian Cancer patientS in First Line Therapy

Who this might be right for
Ovarian CancerFallopian Tube CancerPrimary Peritoneal Carcinoma+1 more
North Eastern German Society of Gynaecological Oncology 640
Testing effectiveness (Phase 2)Looking for participantsNCT06667076
What this trial is testing

Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Janssen Research & Development, LLC 480
Large-scale testing (Phase 3)Study completedNCT01351415
What this trial is testing

Bevacizumab in Combination With Standard of Care Treatment in Participants With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC)

Who this might be right for
Non-Squamous Non-Small Cell Lung Cancer
Hoffmann-La Roche 485
Next Page